Objective: Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption. Adding ZOL to neoadjuvant chemotherapy has been shown to have potential anticancer benefits in women with HER2-negative breast cancer. The objective of the present study was to investigate ZOL’s cost-effectiveness from the perspective of health care payers in Japan. Methods: A Markov model was developed to evaluate the costs and effectiveness associated with ZOL + chemotherapy (CTZ) and chemotherapy (CT) alone over a 10-year time horizon. Monthly transition probabilities were estimated according to JONIE1 (Japan Organization of Neoadjuvant Innovative Expert) Study data and an extrapolated Weibull model. Health outcomes were measured in quality-adjusted life years (QALYs). Costs were calculated using year-2018 Japanese yen (JPY) (1.00 US dollars (USD) = 110.4 JPY). Model robustness was addressed through one-way and probabilistic sensitivity analysis. The costs and QALYs were discounted at a rate of 2% per year. Results: In the base case, the use of CTZ was associated with a gain of 3.94 QALYs. The incremental cost per QALY of the CTZ gain was 681,056.1 JPY (6168.99 USD) per QALY. Conclusion: It is convincing that neoadjuvant CTZ for patients with breast cancer would be expected to have statistically significant clinical efficacy. Addition of ZOL to CT might be a cost-effective option compared with CT alone.
References
[1]
World Health Organization, International Agency for Research on Cancer.
http://globocan.iarc.fr
[2]
Cancer Registry and Statistics (2018) Cancer Information Service, National Cancer Center, Japan. https://ganjoho.jp/reg_stat/statistics/stat/summary.html
[3]
Yamashita, H., Iwase, H., Toyama, T., Takahashi, S., Sugiura, H., Yoshimoto, N., et al. (2011) Estrogen Receptor-Positive Breast Cancer in Japanese Women: Trends in Incidence, Characteristics, and Prognosis. Annals of Oncology, 22, 1318-1325.
https://doi.org/10.1093/annonc/mdq596
[4]
Winter, M.C., Holen, I. and Coleman, R.E. (2008) Exploring the Anti-Tumour Activity of Bisphosphonates in Early Breast Cancer. Cancer Treatment Reviews, 34, 453-475. https://doi.org/10.1016/j.ctrv.2008.02.004
[5]
Coleman, R., De Boer, R., Eidtmann, H., Llomart, A., Davidson, N., Neven, P., et al. (2013) Zoledronic Acid (Zoledronate) for Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole (Z0-FAST Study): Final 60-Month Results. Annals of Oncology, 24, 398-405. https://doi.org/10.1093/annonc/mds277
[6]
Hasegawa, Y., Tanino, H., Horiguchi, J., Miura, D., Ishikawa, T., Hayashi, M., et al. (2015) Randomized Controlled Trial of Zoledronic Acid Plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE1 Study). PLoS ONE, 10, e0143643.
https://doi.org/10.1371/journal.pone.0143643
[7]
Ishikawa. T., Akazawa, K., Hasegawa, Y., Tanino, H., Horiguchi, J., Miura, D., et al. (2017) Survival Outcomes of Neoadjuvant Chemotherapy with Zoledronic Acid for HER2-Negative Breast Cancer. Journal of Surgical Research, 220, 46-51.
https://doi.org/10.1016/j.jss.2017.05.066
[8]
Aft, R.L., Naughton, M., Trinkaus, K. and Weibaecher, K. (2012) Effect of (Neo) Adjuvant Zoledronic Acid on Disease-Free and Overall Survival in Clinical Stage II/III Breast Cancer. British Journal of Cancer, 107, 7-11.
https://doi.org/10.1038/bjc.2012.210
[9]
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., et al. (2013) Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years after Diagnosis of Estrogen Receptor-Positive Breast Cancer: ATLAS, a Randomized Trial. The Lancet, 381, 805-816.
https://doi.org/10.1016/S0140-6736(12)61963-1
[10]
Saito, S., Muneoka, Y., Ishikawa, T. and Akazawa, K. (2017) Cost-Effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing after First-Line Chemotherapy in Japan. Clinical Therapeutics, 39, 2380-2388. https://doi.org/10.1016/j.clinthera.2017.10.017
[11]
(2016) National Health Insurance Price List Japan. Jihou Press, Tokyo. (In Japanese)
[12]
Freedman, G.M., Li, T., Anderson, P.R., Nicolaou, N. and Konski, A. (2010) Health States of Women Conservative Surgery and Radiation for Breast Cancer. Breast Cancer Research and Treatment, 121, 519-526.
https://doi.org/10.1007/s10549-009-0552-5
[13]
Shiroiwa, T., Fukuda, T., Shimozuma, K., Mouri, M., Hasegawa, Y., Doihara, H., et al. (2017) Long-Term Health Status as Measured by EQ-5D among Patients with Metastic Breast Cancer: Comparison of First-Line Oral S-1 and Taxane Therapies in the Randomized Phase III SELECT BC Trial. Quality of Life Research, 26, 445-453.
https://doi.org/10.1007/s11136-016-1388-1
[14]
Central Social Insurance Medical Council Web (2015) Central Social Insurance Medical Council Guideline for Economic Evaluation of Healthcare Technologies for Central Social Insurance Medical Council in Japan. (In Japanese)
https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000104722.pdf
[15]
Ganz, P.A., Cecchini, R.S., Julian, T.B., Margolese, R.G., Costantino, J.O., Vallow, L.A., et al. (2016) Patient-Reported Outcomes with Anastrozole versus Tamoxifen for Postmenopausal Patients with Ductal Carcinoma in Situ Treated with Lumpectomy Plus Radiotherapy (NSABP B-35): A Randomized, Double-Blind, Phase 3 Clinical Trial. The Lancet, 387, 857-865.
https://doi.org/10.1016/S0140-6736(15)01169-1
[16]
Shiroiwa, T., Igarashi, A., Fukuda, T. and Ikeda, S. (2013) WTP for a QALY and Health States: More Money for Severer Health States? Cost Effectiveness and Resource Allocation, 11, 11-22. https://doi.org/10.1186/1478-7547-11-22
http://www.resource-allocation.com/content/11/1/22
[17]
Kroep, J.R., Charehbili, A., Coleman, R.E., Aft, R.L., Hasegawa, Y., Winter, M.C., et al. (2016) Effects of Neoadjuvant Chemotherapy with or without Zoledronic Acid on Pathological Response: A Meta-Analysis of Randomized Trials. European Journal of Cancer, 54, 57-63. https://doi.org/10.1016/j.ejca.2015.10.011
